Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study

OBJECTIVE: To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study. METHODS: FUTURE 5 was a randomised, double-blind, placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C, Mease, Philip J, Gladman, Dafna D, Navarra, Sandra, Bao, Weibin, Gaillez, Corine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124319/
https://www.ncbi.nlm.nih.gov/pubmed/37094983
http://dx.doi.org/10.1136/rmdopen-2022-002939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124319/
https://www.ncbi.nlm.nih.gov/pubmed/37094983
http://dx.doi.org/10.1136/rmdopen-2022-002939

Ejemplares similares